论文部分内容阅读
目的观察比较莫西沙星和左氧氟沙星治疗多耐药肺结核的临床疗效。方法将2012年12月至2013年12月间在我院进行治疗的156例多耐药肺结核患者随机分为观察组和对照组,各78例。两组均采用同样的基础药物治疗,观察组同时使用莫西沙星(0.4g/d),对照组同时使用左氧氟沙星(0.4g/d)o连续给药12个月后观察比较两组患者的累计痰菌累积转阴率及总有效率。结果经过连续12个月的药物治疗后,观察患者最终痰菌累计转阴率为94.87%,总有效率为94.87%,显著高于对照组患者的76.92%和75.64%,差异具有统计学意义(P<0.05)。结论莫西沙星治疗多耐药肺结核患者具有痰菌转阴率高,肺部情况及临床症状改善等优点,值得在临床中推广使用。
Objective To compare the clinical efficacy of moxifloxacin and levofloxacin in the treatment of multi-drug resistant pulmonary tuberculosis. Methods A total of 156 multi-resistant pulmonary tuberculosis patients treated in our hospital from December 2012 to December 2013 were randomly divided into observation group and control group, with 78 cases each. The two groups were treated with the same basic drugs, moxifloxacin (0.4g / d) in the observation group and levofloxacin (0.4g / d) in the control group for 12 months. Phlegm cumulative negative rate and total effective rate. Results After 12 consecutive months of drug treatment, the cumulative negative conversion rate of sputum bacteria was 94.87% and the total effective rate was 94.87%, which was significantly higher than that of the control group (76.92% and 75.64%, respectively), the difference was statistically significant ( P <0.05). Conclusion Moxifloxacin in patients with multidrug-resistant tuberculosis has the advantages of high negative conversion rate of sputum bacteria, improvement of lung conditions and clinical symptoms, and is worthy of promotion in clinic.